Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.920
-0.120 (-5.88%)
At close: Aug 8, 2025, 4:00 PM
1.930
+0.010 (0.52%)
After-hours: Aug 8, 2025, 7:59 PM EDT
Six Flags Entertainment Revenue
Daré Bioscience had revenue of $25.43K in the quarter ending March 31, 2025, with 173.35% growth. This brings the company's revenue in the last twelve months to $25.91K, down -99.08% year-over-year. In the year 2024, Daré Bioscience had annual revenue of $9.78K, down -99.65%.
Revenue (ttm)
$25.91K
Revenue Growth
-99.08%
P/S Ratio
655.86
Revenue / Employee
$1,126
Employees
23
Market Cap
16.99M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
Dec 31, 2022 | 10.00M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DARE News
- 3 days ago - Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - GlobeNewsWire
- 12 days ago - Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - GlobeNewsWire
- 20 days ago - UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar - GlobeNewsWire
- 27 days ago - Crude Oil Moves Lower; Daré Bioscience Shares Jump - Benzinga
- 27 days ago - Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - GlobeNewsWire
- 4 weeks ago - Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - GlobeNewsWire
- 2 months ago - Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders - GlobeNewsWire
- 3 months ago - Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript - Seeking Alpha